Scientists at the ALS Therapy Development Institute are conducting research on this small molecule to determine if it can be an effective treatment for ALS by addressing the hyperexcitability of motor neurons of PALS.
We are currently conducting pharmacokinetic and pharmacodynamic experiments to determine an appropriate dosing stratagem to move this project into later stage preclinical testing, such as survival efficacy screening.
Topics in the Pipeline